Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
I-Mab IMAB
$3.01
-$0.04 (-1.31%)
На 18:02, 12 мая 2023
+1 062.79%
Потенциал через год
Ранг: 1
Ключевые показатели
-
Marketcap
255113316.00000000
-
week52high
13.00
-
week52low
2.73
-
Revenue
-221563000
-
P/E TTM
-1648
-
Beta
0.97751500
-
EPS
-4.32000000
-
Last Dividend
0.00000000
-
Next Earnings Date
31 мар 2023 г. в 12:15
Описание компании
I-Mab, a clinical stage biopharmaceutical company, discovers, develops, and commercializes biologics to treat cancer and autoimmune disorders. It is developing Felzartamab, a CD38 antibody that is in Phase 1b/2a for patients with membranous nephropathy; Eftansomatropin alfa, a long-acting human growth hormone, which has completed Phase 3 clinical trials to treat pediatric growth hormone deficiency; TJ107, a recombinant human IL-7, which is in Phase 2 for cancer treatment-related lymphopenia and cancer immunotherapy; and Lemzoparlimab, a CD47 monoclonal antibody that has completed Phase 2 clinical trial. Its product candidates also includes Enoblituzumab, a humanized B7-H3 antibody that is in Phase 2 to treat head and neck cancer, and other oncology diseases; Efineptakin, a long-acting recombinant human IL-7, which is in Phase 2 clinical trials to treat lymphopenia and cancer immunotherapy; TJ210, a monoclonal antibody against human C5aR1 that is in Phase 1 for the treatment of cancers and autoimmune; Plonmarlimab, a GM-CSF monoclonal antibody for inflammation and CRS-related therapies; Uliledlimab, a CD73 antibody, which is in Phase 2 clinical trials for treating solid tumors and oncology; TJ-L14B, a PD-L1-based tumor-dependent T-cell engager for solid cancers; and TJ-CD4B, a tumor-dependent T cell engager for gastric and other cancers, as well as TJ-L1IF, a PD-L1/IFN-a antibody-cytokine fusion protein for solid tumors and TJ-C64B, a tumor-dependent T-cell engager for ovarian and other cancers. I-Mab has strategic collaboration agreement with AbbVie Ireland Unlimited Company; Sinopharm Group Co. Ltd.; PT Kalbe Genexine Biologics; and Roche Diagnostics. The company was founded in 2014 and is headquartered in Shanghai, the People's Republic of China.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| Needham | Buy | Buy | 17 авг 2022 г. |
| Needham | Buy | Buy | 31 мая 2022 г. |
| HC Wainwright & Co. | Buy | Buy | 31 мая 2022 г. |
| HC Wainwright & Co. | Buy | Buy | 30 мар 2022 г. |
| Needham | Buy | Buy | 01 ноя 2021 г. |
| Piper Sandler | Overweight | Overweight | 31 авг 2022 г. |
| Needham | Buy | Buy | 31 авг 2022 г. |
| HC Wainwright & Co. | Buy | Buy | 31 авг 2022 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
Here's Why IMab Sponsored ADR (IMAB) is Poised for a Turnaround After Losing 26.8% in 4 Weeks
Zacks Investment Research
05 окт 2022 г. в 11:18
IMab Sponsored ADR (IMAB) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
I-Mab: Another CD47 Inhibitor Biotech With Great Potential
Seeking Alpha
27 сент 2022 г. в 14:30
Clearance from China was received to initiate a phase 3 registrational study using Lemzoparlimab for high-risk MDS patients; trial initiation is expected in Q4 of 2022. Results from phase 2 studies using uliledlimab for the treatment of patients with non-small cell lung cancer are expected in Q4 of 2022.
I-Mab (IMAB) H1 2022 Earnings Call Transcript
Seeking Alpha
30 авг 2022 г. в 14:01
I-Mab (NASDAQ:IMAB ) H1 2022 Earnings Conference Call August 30, 2022 9:15 AM ET Company Participants Tyler Ehler – Senior Director of Investor Relations Jingwu Zang – Founder, Chairman and Acting Chief Executive Officer Andrew Zhu – President John Long – Chief Financial Officer Conference Call Participants Kelly Shi – Jefferies Andres Maldonado – H.C. Wainwright Albert Lowe – Piper Tyler Ehler This is Tyler Ehler, I-Mab's Senior Director of Investor Relations.
I-Mab (IMAB) Down After Partner AbbVie Revises Partnership Deal
Zacks Investment Research
18 авг 2022 г. в 14:18
I-Mab's (IMAB) partner AbbVie decides to stop early-stage development of an anti-CD47 antibody therapy targeting multiple cancer indications. IMAB intends to support the candidate's development.